Eupraxia Pharmaceuticals Files Q1 2025 Financial Report

Ticker: EPRX · Form: 6-K · Filed: May 6, 2025 · CIK: 1581178

Sentiment: neutral

Topics: financial-report, 6-K, quarterly-results

TL;DR

Eupraxia Pharma dropped Q1 2025 financials, check the 6-K for the deets.

AI Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 6, 2025, reporting its financial results for the three months ended March 31, 2025. The filing includes consolidated financial statements and management's discussion and analysis. Eupraxia Pharmaceuticals Inc. is incorporated in Canada and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing provides investors with an update on Eupraxia Pharmaceuticals' financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk disclosures.

Key Players & Entities

FAQ

What period do the Consolidated Financial Statements in Exhibit 99.1 cover?

The Consolidated Financial Statements in Exhibit 99.1 cover the three months ended March 31, 2025.

What is the SEC file number for Eupraxia Pharmaceuticals Inc.?

The SEC file number for Eupraxia Pharmaceuticals Inc. is 001-41923.

Where is Eupraxia Pharmaceuticals Inc. located?

Eupraxia Pharmaceuticals Inc. is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.

Which registration statements incorporate Exhibits 99.1 and 99.2 by reference?

Exhibits 99.1 and 99.2 are incorporated by reference into Eupraxia Pharmaceuticals Inc.'s Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).

What type of report is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 6, 2025 regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing